Acute lymphoblastic leukemia (ALL) remains challenging because conventional cytotoxic therapies are often non‑specific, causing bone marrow suppression and immune dysfunction. The reported work presents an in vivo evaluation of a first‑in‑class organomercury–curcumin derivative, α-Mercurin, designed to both reduce leukemic blasts and restore hematopoietic and immune compartments in an autochthonous rat model of ALL.
The study addresses a translational need for therapies that combine targeted anti‑leukemic activity with preservation or recovery of normal hematopoiesis and immune composition.
α-Mercurin is an organomercury–curcumin derivative in which mercury is covalently bonded to the α‑carbon of the curcumin scaffold. This chemical modification is reported to preserve the organic framework and biological properties of curcumin while improving physiological stability and aqueous solubility. The compound was formulated as a sodium salt to enable intravenous delivery.
The design rationale emphasized a multimodal profile: retain curcumin’s biological activity while leveraging mercury conjugation to enhance stability and pharmacologic effect.
Investigations were performed in an N‑nitroso‑N‑ethylurea (ENU)‑induced autochthonous ALL rat model, chosen to preserve intact immune physiology. Previous in vitro and ex vivo studies with α-Mercurin had indicated selective leukemic cytotoxicity driven by reactive oxygen species (ROS), mitochondrial dysfunction, and intrinsic apoptosis; the present study examines whether these effects translate to an immunocompetent in vivo setting.
Comparative outcomes with the nucleoside analog cytarabine were included; specific dosing regimens and statistical parameters were not reported in the source abstract.
Treatment with α-Mercurin produced a significant reduction in circulating leukemic blasts in the ENU‑induced ALL rats. The compound also improved median survival compared to cytarabine-treated animals. The source reports these outcome directions but does not provide numerical survival times, p values, or detailed survival curves in the abstract.
Longitudinal hematological analyses demonstrated progressive restoration across major hematopoietic lineages. The erythroid, myeloid, and megakaryocytic compartments showed recovery during α‑Mercurin treatment, accompanied by sustained control of leucocytosis. These findings suggest that the compound’s anti‑leukemic activity did not produce persistent marrow aplasia and, instead, was associated with marrow functional recovery.
Immunophenotypic profiling was performed across peripheral blood, bone marrow, thymus, spleen, and lymph nodes. The study reports coordinated immune restoration in these compartments after α‑Mercurin treatment, indicating reconstitution of immune cell populations in multiple lymphoid and hematopoietic tissues. The abstract does not enumerate specific cell subset changes or marker panels used.
Histopathological assessment showed reduced leukemic infiltration in treated animals with preservation of tissue architecture. These observations support a disease‑modifying effect of α‑Mercurin at the tissue level, consistent with peripheral blast reduction and marrow recovery.
Biodistribution studies indicated predominant renal clearance of the administered mercury moiety and no detectable accumulation in brain tissue. The authors report substantially higher mercury retention in leukemia‑bearing animals relative to healthy treated controls. A mass‑balance estimate in the study found renal content to account for approximately 1.1% of the total administered mercury.
The abstract specifically notes the absence of detectable brain accumulation in biodistribution assays and emphasizes renal clearance as the primary elimination route. Detailed toxicology, neurologic safety assessment, or comprehensive organ‑by‑organ mercury quantification beyond the renal percentage were not reported in the abstract.
The work is presented as a preprint and has not undergone peer review. The authors disclose related patent filings (Indian, US, and PCT applications) associated with the corresponding author. Funding sources declared include the Indian Council of Medical Research and intramural support from the Chittaranjan National Cancer Institute. Other detailed limitations, full methods, dosing specifics, and comprehensive safety data are not included in the abstract and would require consultation of the full manuscript or subsequent peer‑reviewed publication.
Collectively, the reported in vivo findings characterize α-Mercurin as a multimodal agent that preferentially reduces leukemic burden while supporting recovery of hematopoietic and immune compartments in an immunocompetent ALL rat model, warranting further evaluation and independent peer review.